Thus, wild type p53 with low expression of PRR11 and/or SKA2 lung cancer patients represent a functional regulatory axis of p53-PRR11-SKA2, and hence predicts better prognosis than other groups (Figure 5B). This evidence concerns the gene TP53 and lung cancer.